MeSH term
Frequency | Condition_Probility | Female | 29 | 0.0 |
Humans | 119 | 0.0 |
Pregnancy | 3 | 0.0 |
*CpG Islands | 4 | 5.0 |
DNA Methylation | 40 | 5.0 |
DNA Modification Methylases/*biosynthesis/genetics | 3 | 100.0 |
DNA, Neoplasm/metabolism | 3 | 2.0 |
Gene Deletion | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic | 6 | 0.0 |
*Genes, Tumor Suppressor | 3 | 0.0 |
Promoter Regions (Genetics) | 12 | 0.0 |
RNA, Neoplasm/biosynthesis | 2 | 1.0 |
Research Support, Non-U.S. Gov't | 82 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 48 | 0.0 |
Transcription, Genetic | 11 | 0.0 |
Tumor Cells, Cultured | 24 | 0.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
Animals | 59 | 0.0 |
Cell Line | 24 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/genetics/*metabolism | 10 | 62.0 |
Mice | 42 | 0.0 |
RNA, Messenger/analysis | 6 | 0.0 |
Genes, Tumor Suppressor | 7 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Substrate Specificity | 4 | 0.0 |
Apoptosis | 2 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/*metabolism | 8 | 61.0 |
Gene Silencing | 9 | 2.0 |
Kinetics | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 16 | 0.0 |
*DNA Methylation | 41 | 6.0 |
Gene Expression Profiling | 2 | 0.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Male | 19 | 0.0 |
Proliferating Cell Nuclear Antigen/metabolism | 2 | 0.0 |
Amino Acid Sequence | 13 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/*physiology | 3 | 60.0 |
*Gene Silencing | 4 | 2.0 |
Gene Targeting | 3 | 0.0 |
Molecular Sequence Data | 29 | 0.0 |
Protein p16/genetics | 3 | 3.0 |
CpG Islands/*genetics | 3 | 3.0 |
DNA (Cytosine-5-)-Methyltransferase/*genetics | 16 | 57.0 |
Chromosome Mapping | 5 | 0.0 |
Immunohistochemistry | 7 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 8 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/antagonists & inhibitors/*metabolism | 3 | 100.0 |
Protein Binding | 12 | 0.0 |
Transgenes | 2 | 0.0 |
DNA Methylation/*drug effects | 3 | 20.0 |
Rats | 4 | 0.0 |
Base Sequence | 23 | 0.0 |
Cell Line, Transformed | 3 | 0.0 |
DNA Primers | 7 | 0.0 |
CpG Islands | 12 | 4.0 |
Recombinant Proteins/genetics/metabolism | 3 | 0.0 |
Transfection | 12 | 0.0 |
Cell Transformation, Neoplastic | 5 | 0.0 |
Cyclin D1/metabolism | 2 | 1.0 |
DNA-Binding Proteins/metabolism | 3 | 0.0 |
NIH 3T3 Cells | 2 | 0.0 |
Retinoblastoma Protein/physiology | 2 | 5.0 |
Signal Transduction | 5 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Models, Genetic | 7 | 0.0 |
*Mutation, Missense | 2 | 0.0 |
Blotting, Western | 9 | 0.0 |
COS Cells | 7 | 0.0 |
Cells, Cultured | 3 | 0.0 |
DNA Replication | 3 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Protein Structure, Tertiary | 5 | 0.0 |
S Phase | 3 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/*antagonists & inhibitors | 2 | 100.0 |
DNA Methylation/drug effects | 3 | 13.0 |
Drug Synergism | 3 | 0.0 |
Enzyme Inhibitors/*pharmacology | 4 | 0.0 |
Estrogen Receptor alpha | 4 | 1.0 |
Gene Expression Regulation, Neoplastic/drug effects | 3 | 0.0 |
Histones/metabolism | 6 | 2.0 |
RNA, Messenger/biosynthesis/genetics | 4 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
RNA, Messenger/metabolism | 10 | 0.0 |
Comparative Study | 6 | 0.0 |
Gene Expression Regulation, Enzymologic | 6 | 0.0 |
Mutation | 3 | 0.0 |
Time Factors | 6 | 0.0 |
Cell Cycle | 6 | 0.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/genetics/metabolism | 7 | 77.0 |
CpG Islands/genetics | 4 | 2.0 |
DNA (Cytosine-5-)-Methyltransferase/*biosynthesis/genetics | 2 | 50.0 |
Gene Expression Regulation, Neoplastic | 9 | 0.0 |
Mice, Nude | 2 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Species Specificity | 2 | 0.0 |
Acetylation | 3 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Histones/*metabolism | 5 | 3.0 |
Luminescent Proteins/genetics | 2 | 1.0 |
Plasmids | 2 | 0.0 |
Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/*genetics/metabolism | 4 | 66.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
DNA-Binding Proteins/*genetics/metabolism | 2 | 0.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Cell Line, Tumor | 13 | 0.0 |
Genes, p16 | 2 | 2.0 |
Binding Sites | 5 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/*chemistry | 3 | 100.0 |
DNA-Binding Proteins/chemistry | 2 | 4.0 |
Enzyme Activation | 2 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
English Abstract | 2 | 0.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
Gene Therapy/methods | 2 | 2.0 |
Methylation | 5 | 0.0 |
Promoter Regions (Genetics)/genetics | 5 | 0.0 |
RNA, Messenger/genetics/metabolism | 7 | 0.0 |
Chromatin/metabolism | 5 | 1.0 |
Models, Biological | 3 | 0.0 |
Allosteric Regulation | 2 | 3.0 |
Recombinant Proteins/chemistry/genetics | 2 | 3.0 |
Genes, Reporter | 3 | 0.0 |
Histone Deacetylases/metabolism | 3 | 3.0 |
Mice, Transgenic | 3 | 0.0 |
3T3 Cells | 4 | 0.0 |
Flow Cytometry | 2 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Xenopus | 2 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Cell Division | 3 | 0.0 |
Adult | 7 | 0.0 |
Aged | 9 | 0.0 |
*Chromosomal Proteins, Non-Histone | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Middle Aged | 10 | 0.0 |
*Repressor Proteins | 2 | 0.0 |
*Cell Cycle Proteins | 3 | 0.0 |
DNA, Neoplasm/genetics | 4 | 0.0 |
Polymerase Chain Reaction | 6 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/chemistry/*genetics | 2 | 100.0 |
Oligonucleotides, Antisense/pharmacology | 3 | 1.0 |
Aged, 80 and over | 6 | 0.0 |
Precipitin Tests | 8 | 0.0 |
Catalysis | 2 | 0.0 |
*DNA Replication | 3 | 1.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Gene Expression Regulation | 3 | 0.0 |
Hela Cells | 8 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Response Elements | 2 | 0.0 |
*Transcription, Genetic | 5 | 0.0 |
Cercopithecus aethiops | 4 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Histone Deacetylases/*metabolism | 2 | 1.0 |
Blotting, Southern | 2 | 0.0 |
*Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
Alternative Splicing | 6 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Evolution, Molecular | 2 | 0.0 |
Cloning, Molecular | 4 | 0.0 |
Isoenzymes/genetics | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Centrifugation, Density Gradient | 2 | 0.0 |
Poly Adenosine Diphosphate Ribose/*metabolism | 2 | 15.0 |
DNA/*metabolism | 4 | 0.0 |
Lysine/chemistry | 2 | 2.0 |
Case-Control Studies | 3 | 0.0 |
Gene Dosage | 3 | 0.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Mitosis | 2 | 0.0 |
*Genomic Imprinting | 3 | 1.0 |
In Situ Hybridization | 2 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/genetics | 3 | 30.0 |
Gene Expression | 7 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/biosynthesis/*genetics | 2 | 100.0 |
Azacitidine/*analogs & derivatives/pharmacology | 3 | 4.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
HCT116 Cells | 3 | 13.0 |
Stem Cells | 2 | 1.0 |
*RNA Interference | 2 | 5.0 |
DNA, Complementary/genetics | 3 | 0.0 |
Stem Cells/enzymology | 2 | 33.0 |
Spodoptera/cytology | 2 | 4.0 |
Histone Deacetylases/antagonists & inhibitors | 2 | 4.0 |
Hydroxamic Acids/pharmacology | 2 | 1.0 |
Luciferases/metabolism | 2 | 0.0 |
Protein Interaction Mapping | 2 | 1.0 |
Exons | 2 | 0.0 |
Sulfites/pharmacology | 2 | 6.0 |
Blastocyst/*metabolism | 2 | 8.0 |
Chromosomal Proteins, Non-Histone/*metabolism | 2 | 6.0 |
DNA (Cytosine-5-)-Methyltransferase/metabolism | 4 | 50.0 |
Heterochromatin/*metabolism | 2 | 22.0 |
Repressor Proteins/*metabolism | 2 | 1.0 |
Oligonucleotides, Antisense/*pharmacology | 2 | 2.0 |
Neoplasms/*genetics/metabolism | 2 | 6.0 |
Genome, Human | 2 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Epigenesis, Genetic/*genetics | 2 | 28.0 |
Neoplasms/*genetics | 2 | 0.0 |
Prognosis | 2 | 0.0 |
*Histone-Lysine N-Methyltransferase | 2 | 9.0 |
Cell Division/drug effects | 2 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Methyltransferases/metabolism | 2 | 6.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
